VIE Viela Bio Inc.

53.2
+0.28  (+1%)
Previous Close 52.92
Open 53.05
52 Week Low 25.02
52 Week High 70.66
Market Cap $2,920,894,556
Shares 54,904,033
Float 24,337,864
Enterprise Value $2,522,410,507
Volume 773,249
Av. Daily Volume 924,114
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
VIB7734
COVID-19-Related Acute Lung Injury
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Inebilizumab
IgG4-related disease
Phase 2b
Phase 2b
Phase 2b trial initiated 4Q 2020.
Inebilizumab
Myasthenia gravis
Phase 3
Phase 3
Phase 3 trial initiated 4Q 2020.
VIB7734
Cutaneous lupus erythematosus
Phase 2
Phase 2
Phase 2 trial to commence 1H 2021.
VIB4920
Sjögren’s syndrome
Phase 2b
Phase 2b
Phase 2b enrollment resumed following pause due to COVID-19.
Inebilizumab
Kidney transplant desensitization
Phase 2
Phase 2
Phase 2 enrolment paused due to COVID-19.
VIB4920
Kidney transplant rejection
Phase 2
Phase 2
Phase 2a trial has resumed enrollment following pause due to COVID-19.
Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Approved
Approved
FDA Approval announced June 11, 2020.

Latest News

  1. -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion-

    -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy-

    GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neuromyelitis optica spectrum disorder (NMOSD). Data from…

    -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion-

    -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy-

    GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neuromyelitis optica spectrum disorder (NMOSD). Data from four scientific abstracts were selected for presentations during the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum, which is being held virtually from February 25-27, 2021.

    Among the highlights in patients treated with UPLIZNA® — the first and only FDA-approved B-cell depleter for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD — a reduction of attacks was sustained for the duration of the four-year observation period (with two patients on therapy for more than four years). Consistent with previous clinical results, no new safety signals were observed, regardless of the patient's prior exposure to off-label therapy.

    "Based on data from the OLP, UPLIZNA® demonstrated strong safety and efficacy during the open-label extension for a period of four years, regardless of the patient's previous treatment with off-label therapy, further supporting the drug's ability to provide long-term therapeutic benefits to patients with NMOSD," said Dr. Jorn Drappa, Chief Medical Officer of Viela Bio.

    Presentation Details and Data Highlights

    Poster title: "The N-MOmentum Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Long-Term Open Label Efficacy and Safety Update"

    Poster number: P144

    Presenter: Bruce Cree, M.D., Ph.D., MAS, lead investigator for the N-MOmentum study and Professor of Clinical Neurology at the University of California San Francisco Weill Institute for Neurosciences

    Summary of results:

    • Of the 230 patients randomized and dosed in the N-MOmentum study, 216 entered the OLP with 165/174 (94.8%) of those originally randomized to inebilizumab (RI) and 51/56 (91.1%) originally randomized to placebo (RP);
    • Attack Risk During the OLP

    ○ A sustained, long-term effect on attack risk was observed during the OLP

    ○ Fewer attacks occurred following prolonged treatment exposure. The proportions remaining attack-free were:

    ▪ RI group: 96.3% at 6 months, 92.6% at 1 year and 87.7% at over 4 years

    ▪ RP group: 86.0% at 6 months, 83.6% at 1 year and 83.4% at over 4 years

    ▪ Any inebilizumab group (as defined by all participants who received inebilizumab at any point during the study): 88.3% at 6 months, 84.5% at 1 year and 80.0% at over 4 years

    • Treatment-emergent adverse events (TEAEs) in the OLP

    ○ TEAE incidences per person-year in the OLP were 2.51 (RI) and 3.05 (RP)

    ○ Infusion-related reactions occurred in 5.5% of RI and 13.7% of RP participants, compared with 11.6% in the RCP

    ○ Two participants in the OLP died: one from complications of a severe NMOSD attack and the other from a CNS event of unclear etiology

    • No new safety signals were identified with prolonged inebilizumab treatment and

      inebilizumab-mediated B-cell depletion

    ○ Common TEAEs were similar in the RCP and OLP periods

    ○ Rates of infection or serious infection did not increase with prolonged inebilizumab treatment

    ○ No correlation between rates of infections and concentrations of IgG or IgM were observed

    Poster title: "The Safety and Efficacy of Inebilizumab in Those with Previous Rituximab Exposure"

    Poster number: P145

    Presenter: Michael Levy, Viela Bio

    Summary of results:

    • 17 subjects enrolled in the N-MOmentum study (7.4%) had previous rituximab treatment

    ○ The median time between the last rituximab use and randomization was 1.5 years

    ○ 3 of the 17 participants had attacks on inebilizumab, 1 during the RCP and 2 in the open-label phase

    •  Compared with the rest of the inebilizumab treated group, prior rituximab exposure did not impact efficacy

    ○ The AAR for those with and without prior rituximab exposure was .083 and .102, respectively:

    ○ 7 of 17 patients entered the study as rituximab ‘failures', defined as having an NMOSD attack while on (or within 6 months) of the last dose of rituximab. None of the 7 failures had an adjudicated attack after receiving inebilizumab (mean follow-up 2.6 years)

    ○ Adverse events of interest in this group included infusion reaction (2), infections (16), and cytopenia (1)

    ○ No opportunistic infections occurred

    Summary of Additional Poster Presentations

    Poster Title: "Evaluation of Infusion Reactions and Infusion Times in the N-MOmentum Study of Inebilizumab for NMOSD"

    Poster Number: P138

    Presenter: Mark Tullman, Viela Bio

    Summary of Results: Infusion-related reactions in patients were generally mild and no unexpected safety concerns were identified during continued dosing.

    Poster Title: "Immunoglobin Kinetics and Infection Risk After Long-Term Inebilizumab Treatment for NMOSD"

    Poster Number: P139

    Presenter: Benjamin Greenberg

    Summary of Results: With continued use of UPLIZNA®, a decrease in immunoglobin levels was observed over time, which was not associated with increased rate of infections.

    About Neuromyelitis Optica Spectrum Disorders (NMOSD)

    NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that can be fatal. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies.

    These AQP4 autoantibodies bind primarily to astrocytes in the central nervous system and initiate a cascade of events that lead to neurons damage and the clinical manifestation of NMOSD attack. Commonly, the optic nerve and spinal cord are the sites of NMOSD attack with rare involvement of brain and brainstem. Loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure can all be manifestations of the disease. Each NMOSD attack can lead to further damage and disability. NMOSD occurs more commonly in women and may be more common in individuals of African and Asian descent.

    About N-MOmentum

    N-MOmentum, the largest clinical study ever conducted in NMOSD, was a double-blind, placebo-controlled clinical trial of 213 patients who are anti-AQP4 antibody positive and 17 who are anti-AQP4 antibody negative (n=230). In the randomized controlled phase, patients were randomized to receive two intravenous doses of UPLIZNA® (inebilizumab-cdon) monotherapy or placebo and followed for 6.5 months. Patients were subsequently given the option to enter into an open-label extension in which all patients receive inebilizumab every 6 months. The primary endpoint was time from treatment initiation to occurrence of an NMOSD attack, which was reviewed and confirmed by an independent, blinded external Adjudication Committee. NMOSD attack diagnosis was standardized using 18 clinically meaningful criteria that were developed for the study. The study was completed in November of 2020 with open label follow-up of 2->4 years. More information can be found on clinicaltrials.gov (Study NCT02200770).

    IMPORTANT SAFETY INFORMATION

    UPLIZNA® is contraindicated in patients with:

    • A history of life-threatening infusion reaction to UPLIZNA®
    • Active hepatitis B infection
    • Active or untreated latent tuberculosis

    WARNINGS AND PRECAUTIONS

    Infusion Reactions: UPLIZNA® can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash, or other symptoms. Infusion reactions were most common with the first infusion but were also observed during subsequent infusions. Administer pre-medication with a corticosteroid, an antihistamine, and an anti-pyretic.

    Infections: The most common infections reported by UPLIZNA® -treated patients in the randomized and open-label periods included urinary tract infection (20%), nasopharyngitis (13%), upper respiratory tract infection (8%), and influenza (7%). Delay UPLIZNA® administration in patients with an active infection until the infection is resolved.

    Increased immunosuppressive effects are possible if combining UPLIZNA® with another immunosuppressive therapy.

    The risk of hepatitis B virus (HBV) reactivation has been observed with other B-cell-depleting antibodies. Perform HBV screening in all patients before initiation of treatment with UPLIZNA®. Do not administer to patients with active hepatitis.

    Although no confirmed cases of Progressive Multifocal Leukoencephalopathy (PML) were identified in UPLIZNA® clinical trials, JC virus infection resulting in PML has been observed in patients treated with other B-cell-depleting antibodies and other therapies that affect immune competence. At the first sign or symptom suggestive of PML, withhold UPLIZNA® and perform an appropriate diagnostic evaluation.

    Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating UPLIZNA®.

    Vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation, until B-cell repletion.

    Reduction in Immunoglobulins: There may be a progressive and prolonged hypogammaglobulinemia or decline in the levels of total and individual immunoglobulins such as immunoglobulins G and M (IgG and IgM) with continued UPLIZNA® treatment. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with UPLIZNA® until B-cell repletion especially in patients with opportunistic or recurrent infections.

    Fetal Risk: May cause fetal harm based on animal data. Advise females of reproductive potential of the potential risk to a fetus and to use an effective method of contraception during treatment and for 6 months after stopping UPLIZNA®.

    Adverse Reactions: The most common adverse reactions (at least 10% of patients treated with UPLIZNA® and greater than placebo) were urinary tract infection and arthralgia.

    About Viela Bio

    Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans, objectives of management; our expectations regarding the commercialization of UPLIZNA®; our belief that UPLIZNA® provides prescribing physicians an important new treatment option for patients living with NMOSD; our belief that UPLIZNA® could reduce attacks which can lead to devastating and irreversible disability in patients living with NMOSD; our estimate of the number of people in the U.S. suffering from NMOSD; our estimate of the percentage of patients with NMOSD that test positive for anti-AQP4 antibodies; statements regarding the timing and potential approval of UPLIZNA® in countries outside the United States; potential benefits of UPLIZNA®; our expectations regarding the availability of UPLIZNA®; the commercialization and market acceptance of UPLIZNA®; and our expectations about sufficiency of our existing cash balance and the anticipated impact of the COVID-19 pandemic on our commercialization efforts, business, operations and clinical trials are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" or the negative of these terms or other comparable terminology, which are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various factors may cause differences between our expectations and actual results as discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including without limitation, the risks and uncertainties described in the section entitled "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2019 that was filed with the SEC on March 25, 2020 and our subsequent periodic and current reports filed with the SEC. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Source: Viela Bio

    Contacts:

    Investors:

    Solebury Trout

    Chad Rubin

    646-378-2947

    Media:

    Solebury Trout

    Amy Bonanno

    914-450-0349

     



    Primary Logo

    View Full Article Hide Full Article
  2. - Nolet serves as the Chair of Ambrx's Audit Committee -

    ​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company's Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx's Audit Committee.

    "We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network," said Feng Tian, Ph.D., President and CEO of Ambrx. "His experience in helping transition clinical stage companies into commercially integrated pharmaceutical companies should…

    - Nolet serves as the Chair of Ambrx's Audit Committee -

    ​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company's Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx's Audit Committee.

    "We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network," said Feng Tian, Ph.D., President and CEO of Ambrx. "His experience in helping transition clinical stage companies into commercially integrated pharmaceutical companies should prove invaluable to Ambrx. As Chair of the Audit Committee, he will provide the accounting and financial oversight to support Ambrx through the next stages of the company's growth. I am confident that Chris will prove to be an indispensable board member and look forward to benefiting from his counsel in the years ahead."

    "I am very pleased to join Ambrx's Board at such a pivotal time in the company's history, and to help the development of Ambrx' Engineered Precision Biologics, which could dramatically improve the treatment outcomes for a variety of cancer patients," said Mr. Nolet. "Ambrx recently completed a $200 million private financing round that included some of the world's leading healthcare investors. In addition, Ambrx's lead development candidate, ARX788, has generated promising clinical data, and received Fast Track Designation from the FDA as a potential monotherapy for the treatment of metastatic HER2-positive breast cancer patients."

    Mr. Nolet currently serves on the Boards of Viela Bio (NASDAQ:VIE), where he is Chair of the Audit Committee, PolarityTE, Inc. (NASDAQ:PTE), where he is Chair of the Audit Committee, and Revance Therapeutics (NASDAQ:RVNC), where he is also Chair of the Audit Committee. In addition, Mr. Nolet serves on both the Executive Committee and Finance Committee (Co-Chair) of the California Life Sciences Association (CLSA), and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization.

    Mr. Nolet is the former West Region Life Sciences Industry Leader & Partner at EY, retiring in June of 2019 after more than 38 years in the profession. In addition to serving clients, his responsibilities included leading West Region EY Life Sciences Industry Group, and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. Prior to joining EY, Mr. Nolet was​ ​a partner at PricewaterhouseCoopers where he led the life sciences practice in the western U.S. He holds a B.S. in accounting from San Diego State University and ​is​ a Certified Public Accountant in California (retired).

    About Ambrx

    Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.

    View Full Article Hide Full Article
  3. GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth quarter and full year 2020 operating and financial results after the U.S. financial markets close on Monday, March 1, 2021.

    In light of the agreement and plan of merger by and among Viela Bio, Horizon Therapeutics, Inc., Teiripic Merger Sub, Inc., and Horizon Therapeutics plc, announced on February 1, 2021, Viela will not be hosting a conference call for its fourth quarter 2020 results. Earnings materials will be made available publicly on the Investor…

    GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today announced it will report its fourth quarter and full year 2020 operating and financial results after the U.S. financial markets close on Monday, March 1, 2021.

    In light of the agreement and plan of merger by and among Viela Bio, Horizon Therapeutics, Inc., Teiripic Merger Sub, Inc., and Horizon Therapeutics plc, announced on February 1, 2021, Viela will not be hosting a conference call for its fourth quarter 2020 results. Earnings materials will be made available publicly on the Investor Relations page of Viela's website at www.vielabio.com.

    About Viela Bio

    Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.

    Source: Viela Bio

    Contacts:

    Investors:

    Solebury Trout

    Chad Rubin

    646-378-2947

    Media:

    Solebury Trout

    Amy Bonanno

    914-450-0349



    Primary Logo

    View Full Article Hide Full Article
  4. NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

    • FAST Acquisition Corp. (NYSE:FST)

    FAST Acquisition has agreed to merge with Fertitta Entertainment.  Under the proposed transaction, shareholders of FAST will retain only 5.6% of the combined company.

    • GW Pharmaceuticals plc (NASDAQ: GWPH)

    GW Pharmaceuticals has agreed to be acquired by Jazz Pharmaceuticals.  Under the proposed transaction, shareholders of GW Pharmaceuticals will receive $20.00 worth of shares of Jazz Pharmaceuticals and $200.00 in cash per share.

    • Holicity Inc. (NASDAQ:HOL)

    Holicity has agreed to merge with Astra Space.  Under the proposed transaction, shareholders of Holicity will own only 12% of the combined company.

    • Viela Bio, Inc. (NASDAQ:VIE)

    Viela Bio has agreed to be acquired by Horizon Therapeutics.  Under the proposed transaction, shareholders of Viela Bio will receive $53.00 per share.

    Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. 

    Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at or telephone at (212) 709-8245.  The consultation and case are free with no obligation to you.  Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

    Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.  For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:

    Moore Kuehn, PLLC

    Justin Kuehn, Esq.

    30 Wall Street, 8th Floor

    New York, New York 10005



    (212) 709-8245

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-fst-gwph-hol-and-vie-investors-to-contact-law-firm-301222503.html

    SOURCE Moore Kuehn, PLLC

    View Full Article Hide Full Article
  5. AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, Inc. (Viela), as part of the proposed acquisition of Viela by Horizon Therapeutics plc (Nasdaq: HZNP).

    AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780m upon closing for the sale of the holding, which will be recorded in Reported and Core Other Operating Income and Expense in the Company's financial statements. The divestment is expected to complete by the end of the first quarter of 2021.

    The divestment does not impact the Company's financial guidance for 2020. Guidance for 2021 is anticipated to be issued with full-year 2020 results on 11 February 2021.

    Viela
    Viela (NASDAQ:VIE), headquartered in Gaithersburg…

    AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, Inc. (Viela), as part of the proposed acquisition of Viela by Horizon Therapeutics plc (Nasdaq: HZNP).

    AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780m upon closing for the sale of the holding, which will be recorded in Reported and Core Other Operating Income and Expense in the Company's financial statements. The divestment is expected to complete by the end of the first quarter of 2021.

    The divestment does not impact the Company's financial guidance for 2020. Guidance for 2021 is anticipated to be issued with full-year 2020 results on 11 February 2021.

    Viela
    Viela (NASDAQ:VIE), headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialisation of novel treatments for autoimmune and severe inflammatory diseases. Viela was founded in 2018 as a spinout from AstraZeneca, with clinical and pre-clinical projects from AstraZeneca's inflammation and autoimmunity pipeline.

    AstraZeneca
    AstraZeneca (NASDAQ:AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com 

    — WebWireID269806 —


    View Full Article Hide Full Article
View All Viela Bio Inc. News